Caveolin-1 alleviates angiotensin Ⅱ induced endothelial injury and cerebral microbleed via mitochondrial protection

Chengcheng Li, Xiaoqin Tang, Jie Wang, Hai-jun Duan, Min Xia, Chao Guo, Yujie Chen, Bo Wang, Yongjie Chen, Yin Yi, Weixiang Chen, Hua FengResearch Square 2023 · DOI

Abstract

Cerebral microbleeds are a manifestation of cerebral small vessel disease (CSVD) and a predictor of cerebral hemorrhage. However, the causes of cerebral microbleeds remain unclear. Research on the mechanism of cerebral microbleeds may provide new ideas for the treatment of CSVD. In a mouse model, we show cerebral microbleeds and cognitive impairment with increasing expression of caveolin-1 (Cav-1). Mechanistically, in an in vitro study, we find that Cav-1 knockdown significantly affects the mitochondrial pathway in the cytoplasm and decreases the endothelial viability. Moreover, Cav-1 knockdown induces mitochondrial membrane potential (MMP) depolarization and mitochondria reactive oxygen species (ROS) production. By contrast, overexpression of Cav-1 alleviates the decrease of cell viability, MMP depolarization and mitochondria ROS production induced by angiotensin Ⅱ (Ang Ⅱ). Furthermore, Cav-1 activation significantly improves cerebral microbleeds and cognitive impairment in CSVD mice. We identify Cav-1 as an endogenous protective molecule via mitochondrial protection, and activation of Cav-1 resists microbleeds and cognitive impairment in an animal model of CSVD. Cav-1 might be a candidate therapeutic target for CSVD.

Introduction

Cerebral small vessel disease (CSVD) is a major driver of stroke and vascular dementia, yet it remains a "neglected" condition with few effective treatments. A hallmark of CSVD is the cerebral microbleed—tiny leakages of red blood cells caused by the breakdown of the blood-brain barrier (BBB) and injury to endothelial cells. While hypertension, often modeled via Angiotensin II (Ang II), is known to trigger this damage, the exact molecular "shield" that protects these vessels is poorly understood. This study investigates whether Caveolin-1 (Cav-1), a protein primarily known for forming caveolae in cell membranes, plays a deeper role in protecting the mitochondria of the BBB, thereby preventing the cascade of injury that leads to cognitive impairment.

Materials and Methods

The researchers employed a multi-scale approach combining in vivo animal modeling with in vitro molecular biology:

  • Animal Model: CSVD was induced in C57BL/6 mice using osmotic minipumps to provide a continuous 28-day infusion of Ang II.
  • Cognitive & Pathological Testing: Cognitive function was assessed via nesting experiments (measuring a mouse's ability to build a nest). Microbleeds were quantified using Prussian blue staining and immunofluorescence for fibrin leakage.
  • In Vitro Manipulation: Using the bEND.3 endothelial cell line, the team used siRNA to knock down Cav-1 and lentiviral vectors to overexpress it.
  • Mitochondrial Assays: Mitochondrial membrane potential (MMP) was measured using TMRM staining, and reactive oxygen species (ROS) production was assessed using MitoSOX Red.
  • Therapeutic Intervention: A synthetic peptide, AP-Cav-1, was injected into mice to determine if pharmacological activation of the Cav-1 pathway could rescue the CSVD phenotype.

Results

The Mitochondrial Connection

While Cav-1 is a membrane protein, RNA-Seq transcriptomics revealed that its absence primarily impacts the mitochondria. Approximately 75% of the genes most significantly altered by Cav-1 knockdown were related to mitochondrial function, including the downregulation of key genes like Ccn1 and Nptx1.

Endogenous Compensation and the "Shield" Mechanism

The study found that Ang II exposure increases Cav-1 expression in the brain's blood vessels, suggesting an endogenous compensatory response. However, this natural increase is insufficient to halt disease progression. Mechanistically, Cav-1 acts as a stabilizer for the mitochondrial membrane. Without it, mitochondria undergo depolarization and produce excessive ROS, leading to endothelial cell death and BBB breakdown.

Therapeutic Efficacy of AP-Cav-1

In the lab, overexpressing Cav-1 almost entirely prevented the cell death and mitochondrial ROS production typically induced by Ang II. In vivo, mice treated with the AP-Cav-1 peptide showed significant improvements:

  • Cognitive Rescue: Treated mice performed nearly as well as healthy controls in nesting tasks.
  • Microbleed Reduction: Cav-1 activation significantly decreased the number of microbleeds in the cortex and striatum and reduced fibrin leakage into brain tissue.

Discussion

This research identifies Cav-1 as a critical endogenous protector of the brain’s microvasculature. By maintaining mitochondrial health and preventing oxidative stress in endothelial cells, Cav-1 reduces cerebral microbleeds and reverses cognitive decline in mouse models of CSVD. The use of the AP-Cav-1 peptide demonstrates that the Cav-1 pathway is a viable therapeutic target. Future studies should aim to clarify the specific protein-protein interactions between Cav-1 and mitochondrial machinery and validate these findings in multifactorial models involving aging or diabetes.

Conclusion

Cav-1 serves as a master regulator of endothelial metabolism and a shield against hypertensive injury. Its activation represents a promising strategy for treating CSVD and preventing the progression of vascular dementia.

Summary updated

Abstract

<title>Abstract</title> Cerebral microbleeds are a manifestation of cerebral small vessel disease (CSVD) and a predictor of cerebral hemorrhage. However, the causes of cerebral microbleeds remain unclear. Research on the mechanism of cerebral microbleeds may provide new ideas for the treatment of CSVD. In a mouse model, we show cerebral microbleeds and cognitive impairment with increasing expression of caveolin-1 (Cav-1). Mechanistically, in an in vitro study, we find that Cav-1 knockdown significantly affects the mitochondrial pathway in the cytoplasm and decreases the endothelial viability. Moreover, Cav-1 knockdown induces mitochondrial membrane potential (MMP) depolarization and mitochondria reactive oxygen species (ROS) production. By contrast, overexpression of Cav-1 alleviates the decrease of cell viability, MMP depolarization and mitochondria ROS production induced by angiotensin Ⅱ (Ang Ⅱ). Furthermore, Cav-1 activation significantly improves cerebral microbleeds and cognitive impairment in CSVD mice. We identify Cav-1 as an endogenous protective molecule via mitochondrial protection, and activation of Cav-1 resists microbleeds and cognitive impairment in an animal model of CSVD. Cav-1 might be a candidate therapeutic target for CSVD.
BibTeX
@inproceedings{li2023caveolin,
  author = {Chengcheng Li and Xiaoqin Tang and Jie Wang and Hai-jun Duan and Min Xia and Chao Guo and Yujie Chen and Bo Wang and Yongjie Chen and Yin Yi and Weixiang Chen and Hua Feng},
  title = {{Caveolin-1 alleviates angiotensin Ⅱ induced endothelial injury and cerebral microbleed via mitochondrial protection}},
  booktitle = {Research Square},
  year = {2023},
  doi = {10.21203/rs.3.rs-709689/v2},
}
Figure